Cited 0 time in
Discovery of Novel DUSP4 Inhibitors through the Virtual Screening with Docking Simulations
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Park, Hwangseo | - |
| dc.contributor.author | Jeon, Tae Jin | - |
| dc.contributor.author | Pham Ngoc Chien | - |
| dc.contributor.author | Park, So Ya | - |
| dc.contributor.author | Oh, Sung Min | - |
| dc.contributor.author | Kim, Seung Jun | - |
| dc.contributor.author | Ryu, Seong Eon | - |
| dc.date.accessioned | 2022-07-16T03:27:58Z | - |
| dc.date.available | 2022-07-16T03:27:58Z | - |
| dc.date.issued | 2014-09 | - |
| dc.identifier.issn | 0253-2964 | - |
| dc.identifier.issn | 1229-5949 | - |
| dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/159262 | - |
| dc.description.abstract | Dual specificity protein phosphatase 4 (DUSP4) has been considered a promising target for the development of therapeutics for various human cancers. Here, we report the first example for a successful application of the structure-based virtual screening to identify the novel small-molecule DUSP4 inhibitors. As a consequence of the virtual screening with the modified scoring function to include an effective molecular solvation free energy term, five micromolar DUSP4 inhibitors are found with the associated IC50 values ranging from 3.5 to 10.8 mu M. Because these newly identified inhibitors were also screened for having desirable physicochemical properties as a drug candidate, they may serve as a starting point of the structure-activity relationship study to optimize the medical efficacy. Structural features relevant to the stabilization of the new inhibitors in the active site of DUSP4 are discussed in detail. | - |
| dc.format.extent | 5 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | 대한화학회 | - |
| dc.title | Discovery of Novel DUSP4 Inhibitors through the Virtual Screening with Docking Simulations | - |
| dc.type | Article | - |
| dc.publisher.location | 대한민국 | - |
| dc.identifier.doi | 10.5012/bkcs.2014.35.9.2655 | - |
| dc.identifier.scopusid | 2-s2.0-84926687832 | - |
| dc.identifier.wosid | 000342332500010 | - |
| dc.identifier.bibliographicCitation | Bulletin of the Korean Chemical Society, v.35, no.9, pp 2655 - 2659 | - |
| dc.citation.title | Bulletin of the Korean Chemical Society | - |
| dc.citation.volume | 35 | - |
| dc.citation.number | 9 | - |
| dc.citation.startPage | 2655 | - |
| dc.citation.endPage | 2659 | - |
| dc.type.docType | Article | - |
| dc.identifier.kciid | ART001900428 | - |
| dc.description.isOpenAccess | N | - |
| dc.description.journalRegisteredClass | sci | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.description.journalRegisteredClass | kci | - |
| dc.relation.journalResearchArea | Chemistry | - |
| dc.relation.journalWebOfScienceCategory | Chemistry, Multidisciplinary | - |
| dc.subject.keywordPlus | FREE-ENERGY FUNCTION | - |
| dc.subject.keywordPlus | PHOSPHATASE INHIBITORS | - |
| dc.subject.keywordPlus | BIOCHEMICAL EVALUATION | - |
| dc.subject.keywordPlus | EXPRESSION | - |
| dc.subject.keywordPlus | IDENTIFICATION | - |
| dc.subject.keywordPlus | SOLVATION | - |
| dc.subject.keywordPlus | REVEALS | - |
| dc.subject.keywordPlus | IDENTIFY | - |
| dc.subject.keywordPlus | GENE | - |
| dc.subject.keywordAuthor | Virtual screening | - |
| dc.subject.keywordAuthor | Docking | - |
| dc.subject.keywordAuthor | DUSP4 | - |
| dc.subject.keywordAuthor | Inhibitor | - |
| dc.subject.keywordAuthor | Drug design | - |
| dc.identifier.url | http://koreascience.or.kr/article/JAKO201425560113877.page | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1366
COPYRIGHT © 2024 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
